Enovis (NYSE:ENOV) Hits New 52-Week Low – Time to Sell?

Posted by Stanley Muller on Jul 1st, 2026

Enovis Corporation (NYSE:ENOV – Get Free Report)’s share price hit a new 52-week low on Wednesday . The company traded as low as $19.14 and last traded at $20.7340, with a volume of 2373298 shares traded. The stock had previously closed at $22.02.

Analysts Set New Price Targets

ENOV has been the topic of a number of recent analyst reports. William Blair assumed coverage on Enovis in a research note on Friday, April 17th. They issued an “outperform” rating on the stock. Evercore reaffirmed an “outperform” rating and set a $36.00 target price on shares of Enovis in a research note on Friday, May 8th. Wells Fargo & Company lowered their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a report on Friday, May 8th. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Enovis in a research note on Friday, May 22nd. Finally, Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a research note on Sunday. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and an average price target of $44.50.

Check Out Our Latest Report on ENOV

Enovis Stock Down 5.8%

The company has a market cap of $1.19 billion, a P/E ratio of -1.04 and a beta of 1.38. The stock’s 50-day moving average price is $23.40 and its 200-day moving average price is $23.95. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. During the same period in the previous year, the company posted $0.81 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts forecast that Enovis Corporation will post 3.65 EPS for the current year.

Insider Activity at Enovis

In other news, insider Oliver Engert acquired 1,200 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was purchased at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. The trade was a 2.37% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders purchased a total of 4,200 shares of company stock worth $92,084 in the last ninety days. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

Several hedge funds have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its stake in shares of Enovis by 11.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock worth $20,086,000 after purchasing an additional 78,497 shares during the last quarter. Deroy & Devereaux Private Investment Counsel Inc. bought a new position in shares of Enovis in the fourth quarter valued at approximately $2,929,000. Invenomic Capital Management LP boosted its position in shares of Enovis by 22.7% during the third quarter. Invenomic Capital Management LP now owns 712,669 shares of the company’s stock valued at $21,622,000 after buying an additional 131,705 shares during the last quarter. Impax Asset Management Group plc boosted its position in shares of Enovis by 36.5% during the fourth quarter. Impax Asset Management Group plc now owns 424,130 shares of the company’s stock valued at $11,299,000 after buying an additional 113,500 shares during the last quarter. Finally, Royce & Associates LP grew its holdings in Enovis by 14.6% during the fourth quarter. Royce & Associates LP now owns 826,848 shares of the company’s stock worth $22,027,000 after buying an additional 105,608 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.